Diabetes and dementia: A common link or coincidental coexistence?

Biomedical Reviews

Volumn 18, Issue , 2007, Pages 59-64

  Manning, Stephen R ^a  

^a MORRISTON HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's; Butyrylcholinesterase; Cholesterol; Diabetes

Indexed keywords

EID: 67449132166     PISSN: 1310392X     EISSN: None     Source Type: Journal    
DOI: 10.14748/bmr.v18.68     Document Type: Review

References (45)

1. Tschäpe JA, Hartmann T. Therapeutic perspectives in Alzheimer's disease. Recent Patents CNS Drug Discov 2006; 1: 119-127.
2. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 2006; 27: 190-198.
3. Cukierman T, Gerstein HC, and Williamson JD. Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies. Diabetalgia 2005; 48: 2460-246.
4. Strachen MW, Deary IJ, Ewing FM, Frier BM. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997; 20: 438-445.
5. Bissels GJ, Staekonborg S, Brunner E, Brayne C, Sheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
6. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to a higher-than-optimal blood glucose concentration: comparative risk assessment. Lancet 2006; 368: 1651-1659.
7. Stettler C, Allemann S, Jüni P, Cull CA, Holmann RR, Egger M, et al. Glycaemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomised trials. Am Heart J 2006; 152: 27-38.
8. Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, et al. The action to control cardiovascular risk in diabetes memory in diabetes study (ACCORDMIND): rationale, design and methods. Am J Cardiol 2007; 99: 112i-122i.
9. Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. N Engl J Med 2007; 356: 1842-52
10. Sridhar GR, Thota H, Allam AR, Babu CS, Prasad AS, Divakar C. Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection? Lipids Health Disease 2006; 5: 28.
11. Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007; 69: 1272-1276.
12. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-462.
13. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 2007; 13: RA214-221.
14. Sridhar CR, Lakshmi PV, Rao AA. Phylogenetic tree construction of butyrylcholinesterase sequences in life forms. J Assoc Physicians India 2006; 54: 122-123.
15. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006; 103: 8628-8633.
16. Ghebremedhin E, Thal DR, Schultz C, Braak H. Agedependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains. Neurosci Lett 2002; 320: 25-28.
17. Ghebremedhin E, Thal DR, Schultz C, Braak H, Deller T. Homozygosity for the K variant of BCHE gene increases the risk for development of neurofibrillary pathology but not amyloid deposits at young ages. Acta Neuropathol 2007; 114: 359-363.
18. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005; 102: 17213-17218.
19. Kamal MA, Klein P, Yu QS, Tweedie D, Li Y, Holloway HW, et al. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochem Res 2006 Nov 6: In press.
20. Darvesh S, McDonald RS, Darvesh KV, Mataija D, Conrad S, Gomez G, Walsh R, Martin E. Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem 2007; 15: 6367-6378.
21. Cerbai F, Giovannini MG, Melani C, Enz A, Pepeu G. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Eur J Pharmacol 2007; 572: 142-150.
22. Hashim Y, Shepherd D, Wiltshire S, Holman RR, Levy JC, Clark A, et al. Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects. Diabetologia 2001; 44: 2227-2230.
23. Johansen A, Nielsen EM, Andersen G, Hamid YH, Jensen DP, Glümer C, et al. Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion. Diabetologia 2004; 47: 1437-1441.
24. Nelson T J, Alkon DL. Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem Soc Transact 2005; 33: 1033-1036.
25. Huuter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 2004; 44: 227-238.
26. Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, et al. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol 2001; 60: 778-785
27. Yao ZX, Papadopoulos V. Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J 2002; 16: 1677-1679.
28. Nelson TJ, Alkon DL. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem 2005; 280: 7377-7387.
29. Shobab LA, Hsiung GY, Fledman, HH. Cholesterol in Alzheimer's disease. Lancet Neurol 2005; 4: 841-852.
30. Whitefield JF. Can statins put the brakes on Alzheimer's disease? Expert Opin Investig Drugs 2006; 15: 1479-1485.
31. Reid PC, Uramo Y, Kodama T, Hamakubo T. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 2007; 11: 383-392.
32. Perry TA, Greig NH. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 2004; 5: 565-571.
33. Li L. Is glucagons-like peptide-1 an agent treating diabetes, a new hope for Alzheimer's disease? Neurosci Bull 2007; 23: 58-65.
34. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporatic Alzheimer's disease. J Alzheimers Dis 2006; 9: 13-33.
35. Takeuchi M, Sato T, Takino J, Kobayashi Y, Furuno S, Kikuchi S, et al. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-product (TAGE) in early detection of Alzheimer's disease. Med Hypotheses 2007; 69: 1358-1366.
36. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat model of spontaneous diabetes. Diabetes 2007; 56: 1817-1824.
37. Landreth G. Therapeutic use of agonist of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimer Res 2007; 4: 159-164.
38. Luchsinger JA, Mayeux R. Adiposity and Alzheimer's disease. Curr Alzheimer Res 2007; 4: 127-134.
39. Whitmer RA. The epidemiology of adiposity and dementia. Curr Alzheimer Res 2007; 4: 117-122.
40. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, et al. Caloric restriction attenuates beta-amyloid neuropathology in mouse model of Alzheimer's disease. FASEB J 2005; 19: 659-661.
41. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007; 50: 431-438.
42. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007; 50: 2027-2030.
43. Chaldakov GN, Fiore M, Tonchev Ab, Aloe L. Adipopharmacology, a novel drug discovery approach: A metabotrophic perspective. Lett Drug Des Discov 2006; 3: 503-505.
44. Kim MJ, Lee EY, Lee MY, Chung CH. Adipobiology of diabetes mellitus. Immunol Endocr Metab Agents Med Chem 2007; 7: 123-127.
45. Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res 2004; 146: 279-289.